Literature DB >> 2951819

Comparison of two aerosols containing both fenoterol and ipratropium in a high (Duovent) and low (Berodual) concentration, respectively.

L Frølund, F Madsen, U G Svendsen, B Weeke.   

Abstract

Twenty-one stable asthmatic patients were randomly allocated to be treated with either Duovent (ipratropium bromide 40 micrograms and fenoterol 100 micrograms) and Berodual (ipratropium bromide 20 micrograms and fenoterol 50 micrograms) in a cross-over double-blind design over a 12-week period, each treatment period lasting for 6 weeks. During the study, patients used the test medicine 2 puffs 4 times daily. At the day of inclusion, 6 and 12 weeks after start, a dose-response curve was obtained after inhalation of the test medicine used during the previous 6-week period. Asthma symptoms were recorded in a diary card and morning and evening peak flow was measured. Berodual and Duovent showed a significant bronchodilating effect, the effect of Duovent comparatively more pronounced, but the absolute lung function values after Berodual equalized the effect of Duovent. No difference between peak flow values measured in the morning and evening could be demonstrated. We conclude that no preference between either Duovent or Berodual could be established in the treatment of asthma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2951819     DOI: 10.1159/000195143

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  2 in total

Review 1.  A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.

Authors:  Frank Kässner; Rick Hodder; Eric D Bateman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Long-Term Efficacy and Safety of Ipratropium Bromide plus Fenoterol via Respimat((R)) Soft Misttrade mark Inhaler (SMI) versus a Pressurised Metered-Dose Inhaler in Asthma.

Authors:  Walter Vincken; Theo Bantje; Michelle V Middle; Fronke Gerken; Diane Moonen
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.